 |
| Contact us |
|
| sanofi-aventis |
One Onslow Street
Guildford
Surrey
GU1 4YS
Tel: 01483 505 515
Fax: 01483 535 432 |
| Click here |
|
|
|
|
 | A leading pharmaceutical company devoted to advancing healthcare around the world | |
|
|
|
|
Sanofi-aventis is one of the world’s leading pharmaceutical companies. Global headquarters are located in Paris, France and the U.K. headquarters are in Guildford, Surrey.
|
|
| Seven major therapy areas |
|
Sanofi-aventis focuses its activities on: - cardiovascular medicine
- thrombosis
- oncology
- internal medicine
- metabolic disorders
- diseases of the central nervous system
- vaccines
|
| Great medicines for millions of patients |
|
The sanofi-aventis portfolio of marketed products contains several medicines that are world leaders in their respective classes including: Clexane® (enoxaparin sodium), Plavix® (clopidogrel bisulfate), Telfast® (fexofenadine), Aprovel® (irbesartan), Eloxatin® (oxaliplatin), Lantus® (insulin glargine) and Taxotere® (docetaxel).
|
| A highly productive and innovation R&D organisation |
|
Sanofi-aventis is an industry-leading R&D organisation that is comprised of over 18,000 research staff working in over 25 research and development centres on three continents. Sanofi-aventis maintains its commitment to creating innovative therapeutic treatments and devoted over 4.8 billion euros to its portfolio in 2008. The portfolio includes over 20 compounds presently in advanced stages of development. For more information about sanofi-aventis worldwide, visit www.sanofi-aventis.com.
|
| Updated December 31, 2009 |
|
|
 |
|
Corporate Information
Get more information about sanofi-aventis group
|
|
|
 |
 |
|
|
An easy-to-use interface to ongoing research and completed studies |
|
|
|
|
|
 |
 |
|
| August 30, 2010 |
|
|
Teriflunomide significantly reduced annualised relapse rate and was well-tolerated in MS patients |
|
|
|
|
|
|
|
|
|
|
